A Thomas Look

List of Publications by Year
in descending order

124 papers	9,788 citations	93792 39 h-index	51423 90 g-index
129 all docs	129 docs citations	129 times ranked	16194 citing authors

#	Article	IF	Citations
1	Association of allele-specific methylation of the *ASNS* gene with asparaginase sensitivity and prognosis in T-ALL. Blood Advances, 2022, 6, 212-224.	2.5	11
2	EP300 Selectively Controls the Enhancer Landscape of *MYCN*-Amplified Neuroblastoma. Cancer Discovery, 2022, 12, 730-751.	7.7	64
3	Targeting ganglioneuromas with mTOR inhibitors. Molecular and Cellular Oncology, 2021, 8, 1856621.	0.3	2
4	GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma. Cancer Research, 2021, 81, 2995-3007.	0.4	15
5	Integrative network analysis reveals USP7 haploinsufficiency inhibits E-protein activity in pediatric T-lineage acute lymphoblastic leukemia (T-ALL). Scientific Reports, 2021, 11, 5154.	1.6	10
6	Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. Oncogene, 2021, 40, 5718-5729.	2.6	1
7	Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma. Cancer Research, 2021, 81, 4417-4430.	0.4	31
8	Super-enhancer-based identification of a BATF3/IL-2Râ˜'module reveals vulnerabilities in anaplastic large cell lymphoma. Nature Communications, 2021, 12, 5577.	5.8	21
9	Retinoic acid rewires the adrenergic core regulatory circuitry of childhood neuroblastoma. Science Advances, 2021, 7, eabe0834.	4.7	22
10	*suz12* inactivation in *p53* and *nf1* deficient zebrafish accelerates the onset of MPNSTs and expands the spectrum of tumor types to include adenocarcinoma, leukemia, and soft tissue sarcoma. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	9
11	ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. Science Advances, 2020, 6, eaaz3440.	4.7	47
12	Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors. Journal of Experimental Medicine, 2020, 217, .	4.2	12
13	Discovery of a selective inhibitor of doublecortin like kinase 1. Nature Chemical Biology, 2020, 16, 635-643.	3.9	84
14	LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16516-16526.	3.3	31
15	Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors. Leukemia, 2020, 34, 2992-3006.	3.3	14
16	Discovery of regulatory noncoding variants in individual cancer genomes by using cis-X. Nature Genetics, 2020, 52, 811-818.	9.4	47
17	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia, 2019, 33, 696-709.	3.3	40
18	The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. Leukemia, 2019, 33, 262-266.	3.3	105

#	Article	IF	Citations
19	High *ENT1* and *DCK* gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T‑cell acute lymphoblastic leukemia. Hematological Oncology, 2019, 37, 516-519.	0.8	4
20	Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors. Oncogene, 2019, 38, 6585-6598.	2.6	16
21	Disruption of *asxl1* results in myeloproliferative neoplasms in zebrafish. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	18
22	Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies. PLoS Genetics, 2019, 15, e1008039.	1.5	37
23	ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. Nature Communications, 2019, 10, 5622.	5.8	56
24	Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor. Blood, 2019, 134, 406-406.	0.6	0
25	Cross-Cohort Analysis Identifies a TEAD4–MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. Cancer Discovery, 2018, 8, 582-599.	7.7	119
26	*MYC* Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discovery, 2018, 8, 320-335.	7.7	172
27	Unraveling Neuroblastoma Pathogenesis with the Zebrafish. Cell Cycle, 2018, 17, 395-396.	1.3	2
28	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 1929-1945.	4.2	22
29	Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nature Genetics, 2018, 50, 1240-1246.	9.4	199
30	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. Blood, 2018, 132, 1405-1405.	0.6	5
31	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget, 2018, 9, 6416-6432.	0.8	31
32	Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood, 2017, 129, 3221-3226.	0.6	61
33	Small genomic insertions form enhancers that misregulate oncogenes. Nature Communications, 2017, 8, 14385.	5.8	76
34	Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. Cell Reports, 2017, 18, 2932-2942.	2.9	28
35	Anti‑leukaemic activity of the TYK2 selective inhibitor NDI‑031301 in T‑cell acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 177, 271-282.	1.2	28
36	TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2017, 7, 1336-1353.	7.7	48

#	Article	IF	Citations
37	LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell, 2017, 32, 310-323.e5.	7.7	80
38	Zebrafish B Cell Development without a Preâ€"B Cell Stage, Revealed by CD79 Fluorescence Reporter Transgenes. Journal of Immunology, 2017, 199, 1706-1715.	0.4	40
39	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	7.7	227
40	Neuroblastoma and Its Zebrafish Model. Advances in Experimental Medicine and Biology, 2016, 916, 451-478.	0.8	16
41	Malignant Peripheral Nerve Sheath Tumors. Advances in Experimental Medicine and Biology, 2016, 916, 495-530.	0.8	18
42	Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nature Communications, 2016, 7, 10358.	5.8	79
43	Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. ELife, 2016, 5, .	2.8	29
44	Activation of the LMO2 Oncogene in T-ALL through a Somatically Acquired Neomorphic Promoter. Blood, 2016, 128, 733-733.	0.6	0
45	Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature, 2015, 528, 418-421.	13.7	263
46	A Zebrafish Model of Myelodysplastic Syndrome Produced through *tet2* Genomic Editing. Molecular and Cellular Biology, 2015, 35, 789-804.	1.1	58
47	Abstract A37: Immunohistochemical detection of MYCN protein and MYC protein identifies highly aggressive neuroblastomas. , 2015, , .		0
48	Lâ€Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5qâ€syndrome in a TP53â€independent way. British Journal of Haematology, 2014, 167, 524-528.	1.2	27
49	Loss of function *tp53* mutations do not accelerate the onset of *myc*â€induced Tâ€cell acute lymphoblastic leukaemia in the zebrafish. British Journal of Haematology, 2014, 166, 84-90.	1.2	16
50	Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology, 2014, 16, 1080-1091.	4.6	124
51	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science, 2014, 346, 1373-1377.	6.0	665
52	Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells. Gastroenterology, 2014, 147, 882-892.e8.	0.6	56
53	The Chromatin Remodeling Factor CHD5 Is a Transcriptional Repressor of WEE1. PLoS ONE, 2014, 9, e108066.	1.1	19
54	Abstract IA8: A new class of drugs active in T-ALL is revealed in a zebrafish screen. , 2014, , .		0

#	Article	IF	Citations
55	Â Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells. Blood, 2014, 124, 995-995.	0.6	0
56	<scp>KPT</scp>â€330 inhibitor of <scp>CRM</scp>1 (<scp>XPO</scp>1)â€mediated nuclear export has selective antiâ€leukaemic activity in preclinical models of <scp>T</scp>â€cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British Journal of Haematology, 2013, 161, 117-127.	1.2	149
57	TYK2â€"STAT1â€"BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2013, 3, 564-577.	7.7	122
58	HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase. Blood, 2013, 122, 2528-2528.	0.6	0
59	Novel Inhibitors Of CRM1/XPO1 Nuclear Exporter Exhibit Striking Activity Against AML â€œprimagrafts,â€• Including AML Leukemia Initiating Cells, While Sparing Normal Hematopoietic Cells. Blood, 2013, 122, 3932-3932.	0.6	0
60	A Genetic Screen In Zebrafish Identified Dlst As a Potential Therapeutic Target For Human Acute T-Lymphoblastic Leukemia. Blood, 2013, 122, 1273-1273.	0.6	0
61	Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. DMM Disease Models and Mechanisms, 2012, 5, 881-94.	1.2	72
62	Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. Journal of Biological Chemistry, 2012, 287, 9742-9752.	1.6	89
63	Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 209-221.	7.7	262
64	Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis. Cancer Cell, 2012, 21, 362-373.	7.7	294
65	Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor. Blood, 2012, 120, 3558-3558.	0.6	2
66	The TAL1 Complex Represses the FBXW7 Tumor Suppressor Through Mir-223 in Human T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1296-1296.	0.6	0
67	L-Leucine Improves the Anemia of DBA and the 5q- Syndrome Via Activation of the mTOR Pathway in a p53-Independent Manner. Blood, 2012, 120, 1257-1257.	0.6	0
68	Epigenetic Therapy Inhibits NUP98-HOXA9-Mediated Myeloid Disease â€" Decitabine and Valproic Acid Work Synergistically to Rescue Normal Hematopoiesis in Transgenic Zebrafish.. Blood, 2012, 120, 2391-2391.	0.6	1
69	p63 Mediates an Apoptotic Response to Pharmacological and Disease-Related ER Stress in the Developing Epidermis. Developmental Cell, 2011, 21, 492-505.	3.1	45
70	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1595-1603.	4.2	104
71	Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in T-Cell Acute Lymphoblastic Leukemia,. Blood, 2011, 118, 3453-3453.	0.6	0
72	NOTCH1 Signaling Defines a Leukemia Initiating Cell Population in T-Cell Acute Lymphoblastic Leukemia. Blood, 2011, 118, 1507-1507.	0.6	0

#	Article	IF	Citations
73	Mutationally Activated TYK2 From T-ALL Specimens Exhibits Tranformative Capacity in Cell Lines and Primary Cell Models and T-Lineage Expansion in Mice. Blood, 2011, 118, 74-74.	0.6	14
74	Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. Blood, 2010, 115, 3329-3340.	0.6	70
75	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. Cancer Cell, 2010, 18, 353-366.	7.7	141
76	Oligodendrocyte progenitor cell numbers and migration are regulated by the zebrafish orthologs of the NF1 tumor suppressor gene. Human Molecular Genetics, 2010, 19, 4643-4653.	1.4	42
77	Studying Peripheral Sympathetic Nervous System Development and Neuroblastoma in Zebrafish. Methods in Cell Biology, 2010, 100, 127-152.	0.5	12
78	Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. New England Journal of Medicine, 2010, 363, 1313-1323.	13.9	253
79	Absence of Biallelic <i>TCR</i>Î³ Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3816-3823.	0.8	93
80	Treatment of Zebrafish Models of Ribosomopathies (Diamond Blackfan Anemia (DBA) and 5q- Syndrome) with L-Leucine Results In An Improvement of Anemia and Developmental Defects: Evidence for a Common Pathway?. Blood, 2010, 116, 195-195.	0.6	1
81	Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia.. Blood, 2010, 116, 1042-1042.	0.6	1
82	MYBL2 Is a Candidate Tumor Suppressor Gene In MDS. Blood, 2010, 116, 1865-1865.	0.6	0
83	Cross-Species Comparison of Acquired Genetic Changes In T Cell Malignancy.. Blood, 2010, 116, 1192-1192.	0.6	0
84	Cleavage and Polyadenylation Specificity Factor 1 Is Required for Definitive Hematopoietic Stem Cell Survival In Zebrafish.. Blood, 2010, 116, 1606-1606.	0.6	0
85	Cardiac and vascular functions of the zebrafish orthologues of the type I neurofibromatosis gene <i>NFI</i>. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 22305-22310.	3.3	28
86	Both p53-Dependent and -Independent Pathways Contribute to Erythroid Dysplasia in a Zebrafish Model for Diamond Blackfan Anemia.. Blood, 2009, 114, 177-177.	0.6	2
87	NUP98-HOXA9 Reprograms Embryonic Hematopoiesis, Suppresses Cellular Apoptosis, and Causes Malignant Tissue Infiltrates in Transgenic Zebrafish.. Blood, 2009, 114, 3961-3961.	0.6	0
88	Pten Inactivating Mutations Promote Loss of MYC â€œOncogene Addictionâ€•in a Conditional Zebrafish Model of T-ALL.. Blood, 2009, 114, 3977-3977.	0.6	0
89	Absence of T-Cell Receptor Gene Rearrangements Predicts Induction Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 910-910.	0.6	0
90	Human Nucleophosmin (NPM1) Perturbs Myeloid Development in Zebrafish in Vivo. Blood, 2008, 112, 308-308.	0.6	6

#	ARTICLE	IF	CITATIONS
91	Oncogenic HOXA9 Inhibits Cellular Apoptosis Induced by Ionizing Radiation (IR) in Transgenic Zebrafish. Blood, 2008, 112, 5325-5325.	0.6	0
92	The Role of RNA Helicase Dead Box 18 in Zebrafish Hematopoiesis and Human MDS. Blood, 2008, 112, 500-500.	0.6	0
93	LEF1 Is a Tumor Suppressor in T Cell Acute Lymphoblastic Leukemia. Blood, 2008, 112, 3802-3802.	0.6	0
94	Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes.. Blood, 2007, 110, 120-120.	0.6	4
95	Induction of Death Receptors for TRAIL, a Cytotoxic Factor for GVL Effect, by Oncogenic Fusion E2A-HLF Derived from t(17;19)-Positive Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 2785-2785.	0.6	0
96	Function of Nucleophosmin in Zebrafish Hematopoiesis.. Blood, 2007, 110, 2644-2644.	0.6	0
97	Molecular genetics of acute lymphoblastic leukemia. , 2006, , 272-297.		0
98	Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukmias.. Blood, 2006, 108, 1405-1405.	0.6	0
99	E2A-HLF Fusion Transcription Factor Mediating Aberrant Expression of LMO2 in B-Precursor ALL with t(17;19).. Blood, 2006, 108, 1832-1832.	0.6	0
100	Modifier Genetics in Zebrafish Identify Chk1 and an Associated Survival Pathway as Targets for Pharmacotherapy of MDS/AML with P53 Mutations.. Blood, 2006, 108, 1432-1432.	0.6	0
101	Large Scale Copy Number Variation Upregulates the Expression of MYB in Human T-ALL.. Blood, 2006, 108, 1408-1408.	0.6	0
102	NOTCH1-Induced T-Cell Leukemia in Transgenic Zebrafish.. Blood, 2006, 108, 1825-1825.	0.6	0
103	BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma. Current Biology, 2005, 15, 249-254.	1.8	626
104	Molecular Pathogenesis of MDS. Hematology American Society of Hematology Education Program, 2005, 2005, 156-160.	0.9	53
105	tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 407-412.	3.3	559
106	HOXB9 Is Aberrantly Expressed in Blast Cells in a Subset of Acute Myeloid Leukemia Patients and Supports Proliferation of AML Cell Lines. Blood, 2005, 106, 1613-1613.	0.6	1
107	Activating Notch1 Mutations in Mouse Models of T-ALL.. Blood, 2005, 106, 2609-2609.	0.6	2
108	A Role for fbxo5 in Zebrafish Myelopoiesis.. Blood, 2005, 106, 3608-3608.	0.6	1

#	Article	IF	Citations
109	Induction of CD33 Expression in B-Precursor ALL by E2A-HLF Fusion Transcription Factor Derived from t(17;19).. Blood, 2005, 106, 851-851.	0.6	0
110	Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing Puma.. Blood, 2005, 106, 3624-3624.	0.6	0
111	Pivotal Role of Survivin in Leukemogenesis by E2A-HLF Chimeric Transcription Factor.. Blood, 2005, 106, 2988-2988.	0.6	0
112	A New Recurrent 9q34 Duplication in Pediatric T-Cell Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 89-89.	0.6	1
113	In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7369-7374.	3.3	389
114	Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia. Science, 2004, 306, 269-271.	6.0	2,494
115	Genome-Wide Transcriptional Regulatory Networks Downstream of TAL1/SCL in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2004, 104, 416-416.	0.6	7
116	Slug Plays an Essential Role in the Radioprotection of Hematopoietic Progenitors In Vivo by Antagonizing p53-Mediated Apoptotic Pathways.. Blood, 2004, 104, 31-31.	0.6	0
117	HOXB9 Is Overexpressed in Blast Cells from a Subset of Acute Myeloid Leukemia Patients and Supports Proliferation of AML Cell Lines.. Blood, 2004, 104, 65-65.	0.6	14
118	Epigenetic Suppression of the CTNNA1 Gene, Encoding the α-Catenin Protein, which Is Located in the 5q31 Critical Deleted Region in Malignant Myeloid Disorders with del(5q).. Blood, 2004, 104, 203-203.	0.6	0
119	Fusion of NUP214 to ABL1 on Amplified Extrachromosomal Elements in T-ALL.. Blood, 2004, 104, 141-141.	0.6	3
120	Identification of TAL1/SCL Target Genes through siRNA and Microarray Expression Analysis.. Blood, 2004, 104, 4294-4294.	0.6	8
121	CD34+ Cell Selection Is Required to Accurately Measure HOXA9 Levels by Quantitative RT-PCR in Patients with Myelodysplastic Syndrome.. Blood, 2004, 104, 4733-4733.	0.6	0
122	Molecular pathways in T-cell acute lympho-blastic leukemia: ramifications for therapy. Clinical Advances in Hematology and Oncology, 2004, 2, 779-80.	0.3	3
123	Myc-Induced T Cell Leukemia in Transgenic Zebrafish. Science, 2003, 299, 887-890.	6.0	506
124	E2A-HLF usurps control of evolutionarily conserved survival pathways. Oncogene, 2001, 20, 5718-5725.	2.6	30